Genetic Signatures

Genetic Signatures Altman Z-Score

The Altman Z-Score of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is 0.90. In the previous year, Altman Z-Score was 0.40 — a change of 128.48% (higher).

Altman Z-Score

0.90

YoY

128.48%

Last updated:

Altman Z-Score of Genetic Signatures is 2026 0.90 . Altman Z-Score of Genetic Signatures was 2025 0.40 . It decreases by 128.48% higher compared to the previous year.

The Genetic Signatures Altman Z-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Altman Z-Score
Date
Altman Z-Score
Jan 1, 2019
5.27 AUD
Jan 1, 2020
2.92 AUD
Jan 1, 2021
2.96 AUD
Jan 1, 2022
3.16 AUD
Jan 1, 2023
0.22 AUD
Jan 1, 2024
0.19 AUD
Jan 1, 2025
0.40 AUD
Jan 1, 2026
0.90 AUD
The Genetic Signatures Altman Z-Score history
YEARAltman Z-ScoreYoY
0.90+128.48%
0.40+108.37%
0.19-11.85%
0.22-93.19%
3.16+6.92%
2.96+1.30%
2.92-44.61%
5.27-42.93%
9.24-11.26%
10.41+137.56%
4.38-71.38%
15.32-61.88%
40.17—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Altman Z-Score of Genetic Signatures is 0.90 in 2026.

On Eulerpool you can find the complete historical development of Altman Z-Score Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Genetic Signatures

All Key Metrics — Genetic Signatures